ClinicalTrials.gg
CompletedNCT00474058RECOVERUpdated Jun 22, 2015Results posted

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

A Phase 3 interventional study of Rotigotine and Placebo in Parkinson's Disease, sponsored by UCB Pharma. Completed at 47 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
10th of 42
287 · median 123
Started
2007
with 5 others
Phase 3
20 of 44
none open now
Registered
7th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 10th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 7th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.

Read the detailed description

The objective of this trial is to assess the effects of rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.

After a Screening Period of up to 28 days subjects will be hospitalized for two nights. After the second overnight stay, subjects will be randomly assigned either to rotigotine patch or placebo patch. Afterwards patients will be titrated to their optimal dose. After subjects have reached their optimal dose (or the highest dose) they will be maintained on this dose for a certain period. At the end of maintenance the subjects will be hospitalized for two nights. Afterwards the doses will be continuously decreased.

Efficacy will be assessed by application of sleep quality scores, motor examination scores, and scores to evaluate non-motor symptoms of Parkinsons. Safety assessments include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • rotigotine
  • Neupro®
  • Parkinson's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Early and advanced Idiopathic Parkinson Disease with early morning motor impairment

Exclusion criteria

Exclusion Criteria:

  • Atypical Parkinsonian syndromes
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine transdermal patch

    Drug: Rotigotine

  • Placebo comparator
    Placebo

    Placebo transdermal patch

    Other: Placebo

Interventions

  • Rotigotine transdermal patches: 10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h) Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h

    Also known as: Neupro

  • OtherPlacebo

    Placebo transdermal patches

06

What researchers measure

Primary outcomes

  1. Change in Early Morning UPDRS Part III Score

    The Unified Parkinson´s Disease Rating Scale Part III score is an accepted and validated sumscore of 14 items for the assessment of motor function in Parkinson´s disease. Each of the 14 items in the UPDRS part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities.

    Time frame: From baseline to end of maintenance (after 4 weeks maintenance)

  2. Change in Parkinson's Disease Sleep Scale (PDSS)

    The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sumscore of all 15 questions.

    Time frame: From baseline to end of maintenance (after 4 weeks maintenance)

Secondary outcomes

  1. Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS)

    Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep.

    Time frame: From baseline to end of maintenance (after 4 weeks maintenance)

  2. Change in Number of Nocturias

    Nocturia is the need to get up during the night and interrupt sleep in order to urinate. It is a typical nocturnal symptom of Parkinson´s disease. The change from baseline in number of nocturias was used to evaluate improvements in sleep disorders.

    Time frame: From baseline to end of maintenance (after 4 weeks maintenance)

07

Results

Posted Apr 12, 2010
Limitations and caveats
During the course of the trial, the manufacturing process for rotigotine was changed. At that time, the expiry date for trial medication was Apr 2009, recruitment for SP889 had to be stopped effective on 17 Nov 2008.

Participant flow

A total of 333 subjects were enrolled in this trial and comprised the Enrolled Set (ES). 287 subjects were randomized and all of them received at least 1 dose of trial medication, so they all belong to the Safety Set (SS). 267 subjects belong to the Full Analysis Set (FAS).

Participant flow — Overall Study
MilestoneRotigotinePlacebo
Started19097
Completed16680
Not completed2417
Withdrew: Adverse event116
Withdrew: Lack of efficacy04
Withdrew: Withdrawal by subject117
Withdrew: Other20

Outcome measures

PrimaryChange in Early Morning UPDRS Part III Score

The Unified Parkinson´s Disease Rating Scale Part III score is an accepted and validated sumscore of 14 items for the assessment of motor function in Parkinson´s disease. Each of the 14 items in the UPDRS part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities.

Time frame:
From baseline to end of maintenance (after 4 weeks maintenance)
Reported as:
Mean · units on a scale
Change in Early Morning UPDRS Part III Score
units on a scaleRotigotinePlacebo
Change in Early Morning UPDRS Part III Score-7.0 ± 7.6-3.9 ± 7.3
Statistical analysis
  • Rotigotine vs Placebo · ANCOVA · p = 0.0002 (No p-value adjustment was necessary, since a multiple test procedure in a hierarchical sequentially rejective manner for the primary variable was applied.) · Mean difference (final values): -3.55 · 95% CI -5.37 to -1.73
PrimaryChange in Parkinson's Disease Sleep Scale (PDSS)

The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sumscore of all 15 questions.

Time frame:
From baseline to end of maintenance (after 4 weeks maintenance)
Reported as:
Mean · units on a scale
Change in Parkinson's Disease Sleep Scale (PDSS)
units on a scaleRotigotinePlacebo
Change in Parkinson's Disease Sleep Scale (PDSS)-5.9 ± 7.6-1.9 ± 8.2
Statistical analysis
  • Rotigotine vs Placebo · ANCOVA · p = <0.0001 (No p-value adjustment was necessary, since a multiple testing in a hierarchical sequentially rejective manner for the primary variable was applied.) · Mean difference (final values): -4.26 · 95% CI -6.08 to -2.45
SecondaryChange in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS)

Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep.

Time frame:
From baseline to end of maintenance (after 4 weeks maintenance)
Reported as:
Mean · units on a scale
Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS)
units on a scaleRotigotinePlacebo
Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS)-1.3 ± 1.8-0.9 ± 2.1
Statistical analysis
  • Rotigotine vs Placebo · ANCOVA · p = 0.0301 · Mean difference (final values): -0.41 · 95% CI -0.79 to -0.04
SecondaryChange in Number of Nocturias

Nocturia is the need to get up during the night and interrupt sleep in order to urinate. It is a typical nocturnal symptom of Parkinson´s disease. The change from baseline in number of nocturias was used to evaluate improvements in sleep disorders.

Time frame:
From baseline to end of maintenance (after 4 weeks maintenance)
Reported as:
Mean · nocturias
Change in Number of Nocturias
nocturiasRotigotinePlacebo
Change in Number of Nocturias-0.3 ± 1.3-0.2 ± 1.1
Statistical analysis
  • Rotigotine vs Placebo · ANCOVA · p = 0.8842 · Mean difference (final values): -0.02 · 95% CI -0.29 to 0.25

Adverse events

Collected over Adverse Events (AEs) were collected up to 22 weeks from Visit 1 to the Safety Follow- Up Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—10/191 (5.2%)70/191 (36.6%)
Placebo—5/96 (5.2%)21/96 (21.9%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventRotigotinePlacebo
Oedema peripheralGeneral disorders0/1911/96
Chronic lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1911/96
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1911/96
Cerebrovascular accidentNervous system disorders0/1911/96
Panic attackPsychiatric disorders0/1911/96
Completed suicidePsychiatric disorders0/1911/96
Nephrotic syndromeRenal and urinary disorders0/1911/96
Renal impairmentRenal and urinary disorders0/1911/96
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/1911/96
DiarrhoeaGastrointestinal disorders1/1910/96
Most frequent other events
Most frequent other events
EventRotigotinePlacebo
NauseaGastrointestinal disorders41/1919/96
DizzinessNervous system disorders20/1916/96
DyskinesiaNervous system disorders15/1914/96
HeadacheNervous system disorders13/1915/96

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RotigotinePlaceboTotal
<=18 years000
Between 18 and 65 years8740127
>=65 years9149140
Age, Continuous
Age, Continuous(years)RotigotinePlaceboTotal
Mean64.7 ± 9.464.5 ± 10.464.6 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)RotigotinePlaceboTotal
Female613192
Male11758175
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RotigotinePlaceboTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American213
White16479243
More than one race000
Unknown or Not Reported11819
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/ m^2)RotigotinePlaceboTotal
Mean26.676 ± 4.16426.645 ± 4.56926.665 ± 4.295
Height
Height(cm)RotigotinePlaceboTotal
Mean169.04 ± 9.11170.73 ± 9.27169.60 ± 9.18
Weight
Weight(kg)RotigotinePlaceboTotal
Mean76.6 ± 15.178.0 ± 16.277.1 ± 15.5
08

Study locations

47 sites
  • Reseda, California, United States
  • Ventura, California, United States
  • St. Petersburg, Florida 33701, United States
  • Salisbury, North Carolina 28144, United States
  • Winston_Salem, North Carolina, United States
  • Warwick, Rhode Island, United States
  • Houston, Texas, United States
  • Concord, New South Wales, Australia
  • Adelaide, South Australia, Australia
  • Fitzroy, Australia
  • Innsbruck, 6020, Austria
  • Hyvinkää, Finland
  • Oulu, 90220, Finland
  • Berlin, 10713, Germany
  • Berlin, 12163, Germany
  • Dresden, 01307, Germany
  • Kassel, 34128, Germany
  • Leipzig, Germany
  • Marburg, 35039, Germany
  • Naumburg, Germany
  • Ulm, 89081, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Nyiregyhaza, Hungary
  • Zalaegerszeg, Hungary
  • Chieti, 66013, Italy
  • Milano, Italy
  • Torino, Italy
  • Christ Church, New Zealand
  • Wellington, New Zealand
  • Gdansk, Poland
  • Krakow, Poland
  • Lublin, Poland
  • Olsztyn, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Cape Town, South Africa
  • Capetown, South Africa
  • Johannesburg, South Africa
  • Pretoria/Gauteng, South Africa
  • Tygerberg, South Africa
  • Barcelona, 08036, Spain
  • Madrid, Spain
  • Bristol, United Kingdom
  • Lancashire, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Ghys L, Surmann E, Whitesides J, Boroojerdi B. Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother. 2011 Sep;12(13):1985-98. doi: 10.1517/14656566.2011.604031. Epub 2011 Jul 27. PubMed 21790503 ↗
  • Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014 Mar 6;14:42. doi: 10.1186/1471-2377-14-42. PubMed 24602411 ↗
  • Swick TJ, Friedman JH, Chaudhuri KR, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C. Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER Study. Eur Neurol. 2014;71(3-4):140-7. doi: 10.1159/000355019. Epub 2014 Jan 21. PubMed 24457253 ↗
  • Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011 Jan;26(1):90-9. doi: 10.1002/mds.23441. Epub 2010 Nov 18. PubMed 21322021 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2007
First posted
May 16, 2007
Start
May 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Apr 12, 2010
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00474058
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
May 16, 2007
Start date
May 2007
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Apr 12, 2010
Last update
Jun 22, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion